Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 20085797 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Nelson AC, et al. (2010) AKT regulates BRCA1 stability in response to hormone signaling. Mol Cell Endocrinol 319, 129-42 20085797
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S473-p - Akt1 (human) ▲
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  BG-1, MCF-7 (breast cell), MDA-MB231 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
LY294002 serum inhibit treatment-induced increase
Akt inhibitor VIII serum inhibit treatment-induced increase
estrogen increase
LY294002 estrogen inhibit treatment-induced increase
IGF-1 increase
MG132 increase
LY294002 MG132 inhibit treatment-induced increase
bortezomib increase
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced

T509-p - BRCA1 (human) ▲
Orthologous residues
BRCA1 (human): T509‑p, BRCA1 iso6 (human): ‑, BRCA1 (mouse): S502‑p, BRCA1 (rat): S503‑p
Characterization
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE Akt1 (human)

S694-p - BRCA1 (human) ▲
Orthologous residues
BRCA1 (human): S694‑p, BRCA1 iso6 (human): ‑, BRCA1 (mouse): S686‑p, BRCA1 (rat): S686‑p
Characterization
 Methods used to characterize site in vivo:  immunoprecipitation, mass spectrometry (in vitro), phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  BG-1, MCF-7 (breast cell), MDA-MB231 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE Akt1 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Akt1 (human) pharmacological inhibitor of upstream enzyme, activation of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
estrogen increase
IGF-1 increase
Downstream Regulation
 Effect of modification (function):  protein stabilization


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.